eCTD Publishing for FDA Drug Submissions: What Sponsors Need to Know

eCTD Publishing FDA helps sponsors organise regulatory information, prepare FDA submissions, follow submission standards, check electronic files for errors, and send complete submission packages through the FDA’s electronic submission system.

eCTD Publishing for FDA Drug Submissions

The Electronic Common Technical Document (eCTD) is the standard electronic format accepted by the United States Food and Drug Administration (FDA) for regulatory submissions such as New Drug Applications (NDA), Abbreviated New Drug Applications (ANDA), Investigational New Drug Applications (IND), and Biologics License Applications (BLA).¹ The format also supports electronic submissions to the FDA’s Centre for Drug Evaluation and Research (CDER) and centre for Biologics Evaluation and Research (CBER), including applications, amendments, supplements, and reports. 

FDA provides specific eCTD guidance and submission standards that explain how electronic regulatory submissions should be prepared and submitted. It also provides technical resources, including the eCTD Technical Conformance Guide and FDA Data Standards Catalog, to help companies prepare their submissions correctly.² 

Submissions Covered by eCTD Requirements

The eCTD requirement applies not only to the main Drug applications but also to certain later submissions related to those applications, such as:

• Amendments, supplements and reports: Subsequent submissions related to NDA, ANDA, BLA and commercial IND applications are also covered by the eCTD requirement. 
• Master Files: Master files, such as Drug Master Files (DMFs), are included when they are submitted to support an IND, NDA, ANDA or BLA. 
• Optional submissions: Using the electronic format is encouraged but optional for non-commercial Investigational New Drug applications and submissions concerning blood or blood components, including source plasma.

Electronic Common Technical Document Structure

An Electronic Common Technical Document submission is divided into five modules. Each module contains a different type of information required for the regulatory review.

Table 1

Key eCTD Submission Requirements

Sponsors need to follow the FDA’s guidance and requirements when preparing an eCTD submission. They include: 

• Use the correct version: FDA currently supports eCTD v3.2.2 and v4.0. Sponsors should use the version listed in the FDA Data Standards Catalog. 
• Follow FDA guidance: Sponsors should check the FDA’s eCTD guidance and submission standards before preparing the submission.² 
• Submit a sample when needed: FDA recommends submitting an eCTD sample before the actual submission. This can help sponsors check whether the submission is prepared correctly.⁴ 
• Use the correct submission method: FDA prefers sponsors to submit eCTD submissions through the Electronic Submissions Gateway (ESG). An FDA fillable form should also be submitted with each submission for automated processing.¹ 

eCTD Validation and FDA Submission

Before submitting an eCTD package, sponsors should validate it to identify technical errors and make sure the submission is prepared correctly. FDA also recommends reviewing and validating the eCTD before submission to help avoid submission errors.⁵ 

Figure 1

Sponsor Considerations for eCTD Submission

Sponsors should keep a clear plan for managing their eCTD submission throughout the application process. It includes the following: 

• Keep future submissions consistent: Once an application is converted to eCTD, the sponsor must continue submitting related information in eCTD format. 
• Avoid duplicate paper copies: When an eCTD submission is made electronically, only one electronic copy should be submitted, and paper copies should not be included. 
• Use the eCTD content structure carefully: Sponsors should refer to the Comprehensive Table of Contents Headings and Hierarchy when placing documents in the eCTD.⁴ 

Conclusion

• The FDA Drug application format through eCTD publishing helps sponsors organise applications, amendments, supplements, reports and other regulatory documents in the correct electronic format for FDA submission.
• Using the correct eCTD version, five-module structure, validation process and Electronic Submissions Gateway can help reduce technical errors and submission issues.
• CliniExperts can support clients with eCTD document preparation, compilation, publishing, review and regulatory submission, helping them manage their regulatory documents through the submission process.⁶

References 

1. Research C for DE and. Electronic Regulatory Submission and Review. FDA. August 4, 2026. Accessed September 5, 2026. https://www.fda.gov/Drugs/forms-submission-requirements/electronic-regulatory-submission-and-review

2. Research C for DE and. Electronic Common Technical Document (eCTD). FDA. Published online October 4, 2024. Accessed September 5, 2026. https://www.fda.gov/Drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd

3. U.S. Food and Drug Administration. eCTD Technical Conformance Guide. U.S. Food and Drug Administration; 2024. Accessed September 5, 2026. https://www.fda.gov/media/181847/download?attachment

4. Is the eCTD Format Mandatory? Accessed September 5, 2026. https://www.accessdata.fda.gov/scripts/cder/training/eCTD/submit/submit/fd_03_01_0020.htm

5. Research C for DE and. Submit Using eCTD. FDA. Published online September 18, 2024. Accessed September 5, 2026. https://www.fda.gov/Drugs/electronic-regulatory-submission-and-review/submit-using-ectd

6. Regulatory Outsourcing -CliniExperts. Accessed September 5, 2026. https://cliniexperts.com/strategic-regulatory-outsourcing-for-life-sciences/